Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Equity Average (2021 - 2025)

Maravai Lifesciences Holdings has reported Equity Average over the past 5 years, most recently at $309.1 million for Q4 2025.

  • Quarterly results put Equity Average at $309.1 million for Q4 2025, down 48.05% from a year ago — trailing twelve months through Dec 2025 was $309.1 million (down 48.05% YoY), and the annual figure for FY2025 was $475.0 million, down 30.52%.
  • Equity Average for Q4 2025 was $309.1 million at Maravai Lifesciences Holdings, down from $356.7 million in the prior quarter.
  • Over the last five years, Equity Average for MRVI hit a ceiling of $902.9 million in Q1 2023 and a floor of $184.3 million in Q1 2021.
  • Median Equity Average over the past 5 years was $646.2 million (2022), compared with a mean of $611.3 million.
  • Biggest five-year swings in Equity Average: surged 225.49% in 2022 and later crashed 50.41% in 2025.
  • Maravai Lifesciences Holdings' Equity Average stood at $501.3 million in 2021, then soared by 74.24% to $873.5 million in 2022, then decreased by 3.71% to $841.1 million in 2023, then decreased by 29.26% to $595.0 million in 2024, then plummeted by 48.05% to $309.1 million in 2025.
  • The last three reported values for Equity Average were $309.1 million (Q4 2025), $356.7 million (Q3 2025), and $384.3 million (Q2 2025) per Business Quant data.